About Aurora Diagnostics
Aurora Diagnostics is an independent specialized laboratory company focused on anatomic pathology at locations in the United States. Employing licensed physicians, Aurora Diagnostics provides diagnostics and testing information for the patients of its primary referral sources-dermatologists, OB/GYN professionals, gastroenterologists, urologists, general surgeons, oncologists, and for community hospitals.
Missing: Aurora Diagnostics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Aurora Diagnostics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Aurora Diagnostics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aurora Diagnostics is included in 1 Expert Collection, including Cancer.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Latest Aurora Diagnostics News
Feb 19, 2020
0 Message : FINANCIAL RESULTS FOR THE HALF YEAR ENDED 31 DECEMBER 2019 1. Summary After seven months of trading the Company is on track to achieve the full year earnings guidance issued in August 2019 (6-8% underlying EBITDA growth, Constant Currency, excluding impact of AASB 16 Leases). Underlying EBITDA growth for the half year of 14% (to A$548 million) actual currency (excluding the impact of AASB 16 Leases); 11% Constant Currency. Revenue growth of 15% to A$3.3 billion. Solid organic revenue growth of ~5% (Constant Currency). Net profit growth of 14% to A$254 million (growth 15% excluding AASB 16). Margin accretion in both laboratory and imaging operations. Aurora Diagnostics acquisition performing to expectation. Progressive dividend policy maintained, increase of 1 cent (3%) to 34 cents for the FY2020 Interim Dividend. 2. Commentary Sonic Healthcare today reported a statutory net profit for the half year to 31 December 2019 of A$254 million, on revenues of A$3.3 billion. Sonic's CEO, Dr Colin Goldschmidt, said: "Sonic Healthcare has reported record results for the half year, enhanced by the impacts of the Aurora Diagnostics acquisition completed in January 2019. The Aurora business has performed well since acquisition, in line with our expectations, and cost and revenue synergies are in train. The results for the half again demonstrate the predictable, reliable nature of Sonic's business, with the company on track to deliver the earnings growth guidance set in August 2019. The company achieved 15% revenue growth for the half, including solid organic growth of 5%. Organic revenue growth was particularly strong in our Australian, UK and Swiss laboratory businesses, as well as our Imaging division. On the back of this growth, and through the dedicated efforts of our management teams to continually identify and implement efficiency improvements, both our global laboratory division and the Imaging division expanded their margins versus the comparative period. This was achieved despite the headwinds of PAMA fee cuts in the US and statutory insurance fee quota changes in Germany. The company is well set for future growth, with strong brands and market positions, our binding culture of Medical Leadership, and a balance sheet which provides significant financial flexibility. We continue to target synergistic acquisitions, joint ventures, and contract opportunities, particularly in the US and European laboratory markets. Organic revenue growth remains an integral part of the Sonic story, and our management teams around the globe are constantly pursuing service enhancements and other organic growth initiatives. Just a few examples include expansion of test menus to include increasingly complex tests, including genetic tests, provision of market leading e-health tools, and our ongoing billing system enhancement project in the US. SONIC HEALTHCARE LIMITED ABN 24 004 196 909 • LEVEL 22, GROSVENOR PLACE • 225 GEORGE STREET • SYDNEY • NSW 2000 • AUSTRALIA LOCKED BAG 145 • NORTH RYDE • NSW 1670 • TELEPHONE+61 2 9855 5444 • FACSIMILE +61 2 9878 5066 2 As always, Sonic's achievements are the result of the hard work, passion and creativity of our 37,000 staff and I thank each of them for their contributions to Sonic and to the health care of 120 million patients each year." Dr Colin Goldschmidt Sonic Healthcare Limited (02) 9855 5333 This announcement has been authorised by the Board of Directors of Sonic Healthcare Limited - please refer to the contact details above. For further information regarding the result, please refer to Dr Goldschmidt's PowerPoint Presentation and to Sonic's Appendix 4D Half Year Report, both of which will be posted on the Sonic Healthcare website by 10.00am, 19 February 2020 (www.sonichealthcare.com). Forward-looking statements This media release may include forward-looking statements about our financial results, guidance and business prospects that may involve risks and uncertainties, many of which are outside the control of Sonic Healthcare. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse decisions by Governments and healthcare regulators, changes in the competitive environment and billing policies, lawsuits, loss of contracts and unexpected growth in costs and expenses. The statements being made in this media release do not constitute an offer to sell, or solicitation of an offer to buy, any securities of Sonic Healthcare. No representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including Sonic Healthcare). In particular, no representation, warranty or assurance (express or implied) is given in relation to any underlying assumption or that any forward-looking statement will be achieved. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Given these uncertainties, readers are cautioned to not place undue reliance on such forward-looking statements. SONIC HEALTHCARE LIMITED ABN 24 004 196 909 ∙ 14 GIFFNOCK AVENUE ∙ MACQUARIE PARK ∙ NSW 2113 ∙ AUSTRALIA LOCKED BAG 145 ∙ NORTH RYDE ∙ NSW 1670 ∙ TELEPHONE+61 2 9855 5444 ∙ FACSIMILE +61 2 9878 5066 Attachments
Aurora Diagnostics Frequently Asked Questions (FAQ)
When was Aurora Diagnostics founded?
Aurora Diagnostics was founded in 2006.
Where is Aurora Diagnostics's headquarters?
Aurora Diagnostics's headquarters is located at 11025 RCA Center Drive, Palm Beach Gardens.
What is Aurora Diagnostics's latest funding round?
Aurora Diagnostics's latest funding round is Acquired.
How much did Aurora Diagnostics raise?
Aurora Diagnostics raised a total of $406.4M.
Who are the investors of Aurora Diagnostics?
Investors of Aurora Diagnostics include Sonic Healthcare, Cerberus Capital Management, Summit Partners and GSO Capital Partners.
Who are Aurora Diagnostics's competitors?
Competitors of Aurora Diagnostics include Aurora Analytics, Genoptix, Critical Diagnostics, Cleveland HeartLab, Dr. Lal Path Labs and 12 more.
Compare Aurora Diagnostics to Competitors
Laboratory Partners is a provider of outsourced diagnostic laboratory services.
American Pathology Partners is a network of pathology laboratories and practices dedicated to local and regional healthcare. Based on the individual needs of partner practices and laboratories, the company offers a wide array of world-class support services, including business support, access capital for liquidity and/or growth, and selected esoteric or subspecialty pathology services.
NCI Cancer Hospital is a private oncology centre in Malaysia that combines treatment and clinical research. NCI aims to provide a range of services from diagnosis, laboratory analysis, surgery, chemotherapy and radiotherapy. It operates to GCP and has conducted clinical trials for a number of pharmaceutical companies including Roche, BMS and AstraZeneca.
Oxensis operates a laboratory. It is a a Rutherford Appleton laboratory.
Correlogic Systems, Inc. has developed patented technology and processes with a wide variety of applications for biomarker discovery, disease detection, and new drug discovery. The technology's first application has been in the field of proteomics – the study of human proteins. OvaCheck, a blood test for the early detection of ovarian cancer, is Correlogic's first diagnostic test using its patented "Hidden Patterns" approach. The test is undergoing the final stages of its extensive validation process. Correlogic has entered into marketing agreements with Quest Diagnostics, Inc., and Laboratory Corporation of America for North America. Mitsui & Co., Ltd. and Quest Diagnostics are equity investors in Correlogic.
Progenix Research is an independent contract research organisation offering toxicology services to the world-wide pharmaceutical, biotechnology, agrochemical and industrial chemical industries. It is a newly formed, independent contract research organisation with laboratory facilities currently under construction in Penang, Malaysia. The company's European headquarters are based in Malvern, England, and it also has a histopathology laboratory in Edinburgh, Scotland. A high quality, yet cost-efficient service for toxicology and associated studies will be offered, including studies on pharmaceuticals, biotechnology products, medical devices, food additives, agrochemicals, biocides, and speciality chemicals.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.